BiotechTube
Riboscience

Riboscience

San Diego, United States· Est.
riboscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Founded in 2016 and based in San Diego, Riboscience is a private, pre-revenue biotech developing novel ribose-derived small molecule therapeutics. The company's core asset is its proprietary Nucleoside Platform, which uses structure-guided design to create drug candidates aimed at unique protein targets in human disease. Its most advanced program is an oral ENPP1 inhibitor in Phase 2 trials, targeting significant unmet needs in oncology and virology, including influenza and Hepatitis B. Riboscience's approach aims to generate first-in-class drugs with improved safety and efficacy profiles.

OncologyVirology

Technology Platform

Proprietary Nucleoside Platform utilizing structure-guided design to discover ribose-derived small molecule therapeutics that access unique disease targets, with the goal of creating drugs that are effective, safe, and can modulate immunity.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

Large, underserved markets in oncology (via ENPP1 inhibition) and virology (influenza, HBV) present significant commercial potential.
The platform's focus on oral administration and potential for first-in-class drugs could lead to high-value partnerships or acquisition interest from larger pharma companies.

Risk Factors

High clinical risk associated with its lead Phase 2 ENPP1 inhibitor program.
Faces intense competition in both oncology immunotherapy and antiviral drug development.
As a private, pre-revenue company, it is dependent on external financing, which can be challenging in volatile markets.

Competitive Landscape

The ENPP1 inhibitor space is competitive with several biotech and pharma companies developing candidates. In virology, numerous firms are pursuing next-generation influenza and HBV therapies. Riboscience's differentiation lies in its specialized ribose/nucleoside chemistry platform and structure-guided design approach.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →